You Position: Home > Paper

Comparison of therapeutic effects between CSII plus metformin and CSII plus pioglitazone in short-term T2DM

( views:362, downloads:160 )
Author:
No author available
Journal Title:
CHINESE JOURNAL OF DIABETES
Issue:
4
DOI:
10.3969/j.issn.1006-6187.2010.04.013
Key Word:
糖尿病,2型,持续皮下胰岛素输注;二甲双胍;噻唑烷二酮;胰岛β细胞功能;Diabetes mellitus,type 2;CSII;Metformin;Thiazolidinediones;Islet βcell function

Abstract: Objective To compare the therapeutic effects between continuous subcutaneous insulin infusion (CSII) plus metformin and CSII plus pioglitazone in shortterm T2DM. Methods73 hospitalized patients with short term T2DM were randomly divided into three groups: simple CSII group, CSII plus metformin group, CSII plus pioglitazone group.All cases were treated for 2 weeks, then,fasting plasma glucose(FPG), insulin(Ins), C-peptide(C-P) and high sensitivity CRP(hsC-RP) were measured and postprandial glucose(PG),Ins, CP, hsCRP were measured at 2h after taking 75g glucose. Steadystate model βcell function (HOMA-β) and insulin resistance index (HOMA-IR)were calculated.The treatment costs and changes of above indicators before and after therapy were compared among three groups. Results HOMAβ levels were increased(P<0.05), HOMA-IR levels decreased significantly(P<0.05) in metformin and pioglitazone groups compared with simple CSII group.The glucose target time and treatment costs were reduced, and insulin dosage decreased significantly in metformin group compared with the simple CSII and pioglitazone groups(P<0.05). ConclusionsCompared with simple CSII,CSII plus metformin or pioglitazone could improve the function of pancreatin βcell and reduce IR. CSII plus with metformin versus pioglitazone could decrease insulin dosage and treatment costs and shorten hospitalization period.

WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn